CureVac (NASDAQ:CVAC) Given Neutral Rating at UBS Group

UBS Group reissued their neutral rating on shares of CureVac (NASDAQ:CVAC) in a report published on Thursday,Benzinga reports. The brokerage currently has a $5.50 price target on the stock, down from their prior price target of $12.00.

Other equities research analysts also recently issued reports about the company. Jefferies Financial Group reissued a “hold” rating and issued a $5.00 price objective (down from $7.00) on shares of CureVac in a research note on Friday, June 13th. Citizens Jmp cut shares of CureVac from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 12th. JMP Securities reaffirmed a “market outperform” rating and set a $10.00 target price on shares of CureVac in a research report on Wednesday, May 28th. Finally, Citigroup downgraded CureVac to a “market perform” rating in a research report on Thursday, June 12th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, CureVac presently has a consensus rating of “Hold” and an average price target of $6.83.

CureVac Stock Down 0.7%

NASDAQ CVAC opened at $5.40 on Thursday. CureVac has a 12 month low of $2.37 and a 12 month high of $5.72. The company has a market capitalization of $1.21 billion, a P/E ratio of 5.87 and a beta of 2.49. The company’s 50 day simple moving average is $4.19 and its 200 day simple moving average is $3.63. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.64.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a return on equity of 30.89% and a net margin of 35.44%. The business had revenue of $0.94 million during the quarter, compared to analyst estimates of $4.27 million. Equities research analysts expect that CureVac will post 0.72 earnings per share for the current fiscal year.

Institutional Trading of CureVac

A number of hedge funds have recently modified their holdings of the company. Plato Investment Management Ltd acquired a new position in CureVac in the first quarter worth about $84,000. Millennium Management LLC grew its stake in shares of CureVac by 10.3% during the first quarter. Millennium Management LLC now owns 1,816,984 shares of the company’s stock valued at $5,033,000 after purchasing an additional 169,947 shares during the last quarter. Integrated Wealth Concepts LLC boosted its position in CureVac by 25.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after buying an additional 3,000 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in CureVac in the first quarter worth about $142,000. Finally, State of Wyoming acquired a new stake in shares of CureVac during the 1st quarter worth approximately $317,000. Institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.